Here we describe a glycan microarray constructed by using standard robotic microarray printing technology to couple amine functionalized glycans to an amino-reactive glass slide. The array comprises 200 synthetic and natural glycan sequences representing major glycan structures of glycoproteins and glycolipids. The array has remarkable utility for profiling the specificity of a diverse range of glycan binding proteins, including C-type lectins, siglecs, galectins, anticarbohydrate antibodies, lectins from plants and microbes, and intact viruses.
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carbohydrate ͉ lectin ͉ microarray ͉ glycoprotein ͉ glycolipid W ith 50% or more of all proteins carrying glycan chains, glycomics has emerged with proteomics as an area for development and exploration in the postgenomics era. As vital constituents of all living systems, glycans are involved in recognition, adherence, motility, and signaling processes (1, 2) . Glycan binding proteins (GBPs) play a significant role in decoding the information content of glycans by recognizing and specifically binding to glycosylated protein and lipid ligands. However, the enormous complexity of GBP-ligand interactions and the absence of well defined glycan libraries and efficient analytical screening methods have limited analysis of their specificity and elucidation of their biological roles. To address these limitations, development of reliable and efficient tools for analysis of GBP specificity is needed.
In recent years, several approaches for construction of glycan arrays for analysis of GBP specificity (3-6) have emerged. Each format differs in the type of glycans and the manner in which they are displayed. Some use noncovalent attachment to plastic or nitrocellulose membrane (6) (7) (8) (9) (10) (11) (12) , and others use covalent attachment to plastic, gold, or glass (6, (13) (14) (15) (16) (17) (18) (19) (20) . The glycans displayed range from a limited number of 5-45 exemplary structures representing terminal sequences on glycoprotein or glycolipid glycans (6, 7, (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , to libraries of defined glycans, proteoglycan fragments, and microbial polysaccharides (8) (9) (10) .
In this article we describe a glycan array format that uses standard robotic printing technology for the creation of a diverse glycan array with demonstrated applicability for profiling the specificity of a wide variety of GBPs. This array uses commercially available amine-reactive N-hydroxysuccinimide (NHS)-activated glass slides, which allow rapid covalent coupling of amine-functionalized glycans or glycoconjugates. Advantage was taken of the existence of a glycan library comprising Ͼ200 synthetic and natural structurally defined terminal sequences of glycoprotein and glycolipid glycans l developed for an ELISAbased array (8) , which could be readily modified to contain amino-functionalized linkers for covalent coupling to NHSactivated glass slides. We demonstrate the utility of this array for purchased from Vector Laboratories. Rabbit anti-influenza virus A͞PR͞8͞34 was from the World Influenza Centre, London. Other reagents and consumables were from commercial sources with highest possible quality.
Glycan Array Fabrication. Microarrays were printed by robotic pin deposition of Ϸ0.6 nl of various concentrations of aminecontaining glycans in print buffer (300 mM phosphate, pH 8.5 containing 0.005% Tween-20) onto NHS-activated glass slides. Each compound was printed at two concentrations (100 and 10 M), and each concentration was used in a replicate of six. Printed slides were allowed to react in an atmosphere of 80% humidity for 30 min followed by desiccation overnight. Remaining NHS groups were blocked by immersion in buffer (50 mM ethanolamine in 50 mM borate buffer, pH 9.2) for 1 h. Slides were rinsed with water, dried, and stored in desiccators at room temperature before use.
GBP Binding Assay. Printed slides were analyzed without any further modification of the surface. Slides were incubated in either a one-step procedure with labeled proteins or a sandwich procedure in which the bound GBP was overlaid with labeled secondary antibodies or GBPs precomplexed with labeled antibodies. GBPs were added at a concentration of 5-50 g͞ml in buffer (usually PBS containing 0.005-0.5% Tween-20). Secondary antibodies (10 g͞ml in PBS) were overlaid on bound GBP. GBP-antibody precomplexes were prepared in a molar ratio of 1:0.5:0.25 (5-50 g͞ml) for GBP͞2°antibody͞3°antibody, respectively (15 min on ice). The samples (50-100 l) were applied either directly onto the surface of a single slide and covered with a microscope coverslip or applied between two parallel slides separated by thin tape and pressed together by paper clips (34) and then incubated in a humidified chamber for 30-60 min. Slides were subsequently washed by successive rinses in (i) PBS-0.05% Tween, (ii) PBS, and (iii) deionized water, then immediately subjected to imaging. Serum samples were typically used at dilutions of 1:25, and 0.4-0.8 ml was applied directly onto the slide surface without any cover glass. The slides were gently rocked at room temperature for 90 min followed by detection with secondary antibodies (Table 1) . Whole virus was applied (0.8 ml) at a concentration of 100 g͞ml in buffer (PBS containing 0.05% Tween-20) containing the neuraminidase inhibitor oseltamivir carboxylate (10 M). The slides were gently rocked at room temperature for 90 min followed by detection with secondary antibodies in the presence of the neuraminidase inhibitor (Table 1) .
Image Acquisition and Signal Processing. Fluorescence intensities were detected by using a ScanArray 5000 (PerkinElmer) confocal scanner, and image analyses were carried out by using IMAGENE image analysis software (BioDiscovery, El Segundo, CA). Signal-to-background was typically Ͼ50:1, and no background subtractions were performed. Data were plotted by using Microsoft EXCEL software.
Results
Glycan Array Design. We adopted a strategy for covalently attaching a defined glycan library to microglass slides by using standard microarray printing technology (Fig. 1) . The use of an aminoreactive NHS-activated microglass surface allows covalent attachment of glycans containing a terminal amine by forming an amide bond under aqueous conditions at room temperature. The compound library of 200 glycoconjugates comprises diverse and biologically relevant structures representing terminal sequences of glycoprotein and glycolipid glycans (see Methods and Supporting Methods) l (22) (23) (24) (25) (26) 35) . Glycan structures detected by GBPs analyzed in this article are listed in Fig. 2 , and a complete glycan listing is provided in Fig. 7 , which is published as supporting information on the PNAS web site. In addition, exemplary symbol structures summarizing the principal specificities of each GBP are depicted in each figure.
Optimization of Glycan Printing. Length of time of the printing process was a concern because the moisture-sensitive NHS slides would be exposed to air during the procedure. Binding of fluorescein-labeled Con A was used as a measure of ligand coupling. Maximal binding of Con A to high mannose glycans, 134-138, was obtained at concentrations Ͼ50 M, with Ͻ10% variation in maximal binding observed with printing times up to 5 h, as shown in Fig. 3A for compound 136. For the complete array, standard printing concentrations of 100 and 10 M of each glycan were selected to represent saturating and subsaturating levels, respectively, of the printed glycan. All samples were printed in replicates of six to generate an array of Ͼ2,400 spotted ligands per glass slide, including controls.
General Approach for Profiling GBP Specificity. In general, GBPs have low affinity for their ligands and would not be expected to bind with sufficient avidity to withstand washing steps to remove unbound protein (36) . For this reason, our routine approach is to create multivalency as necessary to mimic the multivalent interactions that occur in nature. GBPs evaluated here and the degree of multivalency used to achieve robust binding is summarized in Table 1 . The valency required for binding ranged from 2 to 12. In several cases monovalent GBPs were evaluated as divalent recombinant Ig-Fc chimeras, and in others higher valency was achieved through the use of secondary antibodies. Binding was detected by including a fluorescent label either on the GBP or secondary antibody. Analysis of Specificities of Human GBPs. Three major families of mammalian GBPs are involved in cell surface biology through recognition of glycan ligands: C-type lectins, siglecs, and galectins. One exemplary member from each class was selected for analysis (Fig. 4) . DC-SIGN, a member of the group 2 subfamily of the C-type lectin family, is a dendritic cell protein implicated in innate immunity and the pathogenicity of HIV-1 (41) . As shown in Fig.  4 , a recombinant DC-SIGN-Fc recognized two classes of glycans, various fucosylated oligosaccharides with the Fuc␣1-3GlcNAc and Fuc␣1-4GlcNAc oligosaccharides found as terminal sequences on N-and O-linked oligosaccharides (7, 8, 51, 66, 94 , and 102), and mannose-containing oligosaccharides terminated with Man␣1-2-residues (135-138, 144, and 145), consistent with specificities found by other groups (8, 28, 42) .
CD22, a member of the Ig superfamily lectins (Siglecs), is a well known negative regulator of B cell signaling and binds selectively to glycans with Sia␣2-6Gal-sequences (32, (43) (44) (45) . CD22 bound exclusively to the seven structures containing the terminal Sia␣2-6Gal␤1-4GlcNAc-sequence including a biantennary N-linked glycan (154, 187-189, and 199 ). An additional 6-O-GlcNAc sulfation (Neu5Ac␣2-6Gal␤1-4[6Su]GlcNAc-183) appeared to enhance binding relative to the corresponding nonsulfated glycan, suggesting that this glycan could be a preferred ligand for human CD22.
Galectins are a family of ␤-galactoside binding lectins that bind terminal and internal galactose residues (46). Galectin-4 has been identified as a possible intracellular mediator with antiapoptotic activity (33, 47) . By comparing galectin-4 binding to saturated glycans (printed at 100 M concentration) with binding to subsaturated glycans (printed at 10 M concentration), preferred binding specificities were revealed. In particular, Gal␣1-3-linked to lactose (35-37), Fuc␣1-2-linked to lac(NAc) (100, 103, and 105-107), or R-GlcNAc␤1-3-linked to lactose (123), as well as 3Ј sulfation (11) (12) (13) (14) (15) (16) , substantially enhanced the affinity. This specificity profile is similar to that reported for a rat ortholog of galectin-4 (48, 49).
Glycan-Specific Antibodies. We have analyzed monoclonal and polyclonal antiglycan antibodies from three different sources (Fig. 5) . The commercial leukocyte differentiation antigen ␣CD-15 has been documented to recognize a carbohydrate antigen, Lewis x (Gal␤1-4[Fuc␣1-3]GlcNAc). When evaluated on the array it is highly specific for Lewis x structures (7, 8, and 66) and does not recognize the same structure modified by additional sialylation (161), sulfation (26) , fucosylation (102), or LacNAc extension (73). One of the most studied human anti-HIV mAbs is 2G12, which neutralizes a broad spectrum of natural HIV isolates via recognition of high mannose-type N-linked glycans on the major envelope glycoprotein, gp120 (27, 30, 31, 50, 51 (14, 27, 42) . In addition, of the series of natural high mannose-type N-glycans, 2G12 exhibited preferred binding to Man8 glycans (144) relative to Man5, Man6, Man7, or Man9 glycans (140, 142, 143, and 145) .
To test the array against more complex samples, antiglycan antibodies present in human serum were investigated. After incubation with serum, bound IgG, IgA, and IgM were detected by using labeled anti-human IgG͞A͞M antibody. A surprising diversity of antibody specificities was observed. It was remarkably consistent among samples from 10 individuals as indicated in Fig. 5 . This profile of human antiglycan antibodies detects the ABO blood group fragments (variously represented in different individuals) (32, 81, and 83), mannose fragments (135-139), ␣-Gal-(31-37), and ganglioside-epitopes (55- 59, 132, and 168) , as well as fragments of the Gramnegative bacterial cell wall peptidoglycan (127) and rhamnose (200). Notably, glycans containing the Gal␤1-3GlcNAc substructure were consistently detected (12, 61, 62, 132, 150 , and 168) except when fucosylated (25, 51, 94, and 100) , thus generating the human blood group antigens H, Lewis a or Lewis b . All of these structures can be identified as either blood group antigens or fragments of microorganisms (e.g., bacteria, yeast, etc.) to which humans are exposed.
Analysis of Bacterial and Viral GBPs. CVN is a cyanobacterial protein that can block the initial step of HIV-1 infection by binding to high mannose groups on the envelope glycoprotein gp120 (42, 52) . On the array, CVN specifically recognized the synthetic fragments bearing terminal Man␣1-2-residues (135-138), as well as high mannose glycans with one or more Man␣1-2-termini (140-145), in keeping with its reported specificity (Fig. 6 ). In addition, CVN bound to several lacto-and neolacto-structures (53, 62, 75, and 176) .
Inf luenza viruses exhibit specificity in their ability to recognize sialosides as cell surface receptor determinants through the viral binding protein, the hemagglutinin. Depending on the species of origin, the hemagglutinin has specificity for sialosides with sialic acid in the NeuAc␣2-3Gal or NeuAc␣2-6Gal linkage (53) (54) (55) . While the intrinsic affinity of sialosides for the hemagglutinin is weak (K d Ϸ2 mM), binding is strengthened through polyvalent interactions at the cell surface (56) . Results shown in Fig. 6 reveal the binding of a recombinant avian H3 hemagglutinin (duck͞Ukraine͞1͞63) bound to Neu5Ac␣2-3-linked to galactosides (24, 162-169, and 176-180) , but not to any Neu5Ac␣2-6-or Neu5Ac␣2-8-linked sialosides. Intact inf luenza viruses, such as A͞Puerto Rico͞8͞34 (H1N1), were also strongly bound to the array. The overall affinities are consistent with previous findings and show specificity for both a2-3 and a2-6 sialosides (57). Detailed fine specificities were also revealed such as binding to Neu5Ac␣2-3-and Neu5Ac␣2-6-linked to galactosides (24, 151, 157, 161-180,  182-190, and 199) , as well as certain O-linked sialosides.
Discussion
The glycan microarray presented in this article uses standard robotic printing, scanning, and image analysis software used for DNA microarrays. The combination of using amine-functionalized glycans with the NHS-activated glass surface results in robust and reproducible covalent attachment of glycans with no modifications of standard DNA printing protocols. The array can be used with no further preparation of the surface for assessing the specificity of a wide variety of GBPs, yielding uniformly low backgrounds regardless of the labeled protein used for detection. Moreover, only 0.1-2 g of GBP is needed for optimal signal, Ͼ100-fold less than required for our ELISA-based array that uses predominately the same glycan library. n The array performed well for a wide variety of GBPs, confirming primary specificities documented by other means, and revealing unique aspects of fine specificity not previously recognized.
It is noteworthy that substantial signal enhancement is achieved for GBPs on the array when multivalent displays of the glycan binding domain are used (Table 1 ). This effect reflects the low intrinsic affinity of GBPs for their preferred glycan ligands, with typical K d values of 1-1,000 M (36). In general, multivalent display of the GBPs will tend to amplify differences of specificity relative to the intrinsic affinities and reveal biologically important specificities. As a case in point, the difference in intrinsic affinities of influenza virus H3 hemagglutinin for ␣2-3 and ␣2-6 sialosides is only 2-fold, yet multivalent display of hemagglutinins amplifiy the difference to 100-to 1,000-fold for specific adsorption of the virus to cell surfaces bearing the preferred sequence (53, 56) .
The importance of valency extends to comparing specificities of GBPs obtained by using different assays. In the case of DC-SIGN, the dual specificities for mannose-containing glycans and fucosecontaining glycans (including Lewis x and Lewis a structures) observed previously (8) , were also observed here. However, the binding of the series of natural branched high mannose-containing N-glycans (142-145) was low in the present study and nearly equal to that of the fucosides in the study by Guo et al. (8) . This apparent discrepancy may be related to the differences in the multivalent presentation of the GBP (dimeric Fc chimera vs. renatured tetramer), the presentation of the oligosaccharide, or both. In this study we have saturated the surface of the NHS-derivatized glass with glycan to similar density as evidenced by the binding of Con A (Fig. 3) . In the Guo et al. study, biotinylated glycans were adsorbed to streptavidin-coated wells of an ELISA plate, providing a lower uniform density of tetrameric streptavidin binding up to four oligosaccharides.
In addition to the utility of the glycan array for analysis of GBP specificity, this system has potential in therapeutic developments. A striking result is the ability to reproducibly detect a variety of antiglycan antibody specificities in crude human serum. This finding raises the possibility of the use of the array in screening for glycan-specific antibodies with potential for diagnosis in patients with microbial infections, cancer, and autoimmune disease or after xenotransplantation.
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